Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC Meeting Abstract
| Authors: | Yu, H. A.; Baik, C. S.; Gold, K.; Hayashi, H.; Johnson, M.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W. C.; Yang, J.; Karam, S.; Qi, Z.; Qiu, Y.; Chen, S.; Yu, C.; Jänne, P. A. |
| Abstract Title: | Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S1189 |
| End Page: | S1190 |
| Language: | English |
| ACCESSION: | WOS:000573469102693 |
| DOI: | 10.1016/j.annonc.2020.08.2295 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA6 -- Source: Wos |
